Molbio Diagnostics IPO: Subscribe Ratings Surpass Expectations Despite Concentration Risk Concerns, Say Brokers.
The Molbio Diagnostics IPO has generated significant interest among Indian investors, opening for subscription between 10 August and 12 August 2026 with a price band of INR 768-807 per share. The total issue size stands at INR 939.70 crore, consisting of a fresh issue of 2,480,246 shares and an offer for sale of 9,166,000 shares. Despite a sluggish start, as reflected in the subscription data showing an overall issue at only 0.18x on Day 1, leading brokerages remain cautiously optimistic. The minimum lot size for retail investors is set at 18 shares, translating to a minimum investment of approximately INR 14,526 at the upper price band.
Brokerage sentiment towards the IPO is mixed but leans towards favorability, primarily driven by the company’s unique positioning as the only Indian manufacturer with a WHO-endorsed rapid TB molecular test. Ventura Securities rates the issue as a Subscribe, pointing to Molbio’s sustainable revenue model stemming from its proprietary Truenat test kits. Others, such as SMC Global and Marwadi Shares, express cautious optimism, noting the potential for strong growth alongside significant risks associated with government procurement reliance, which comprises about 84.56% of the company’s total finished goods revenue.
For Indian investors, this IPO encapsulates both opportunity and caution. While the backing from anchor investors and the company’s innovative approach suggest potential for growth, risks associated with revenue concentration and a high cash conversion cycle must also be considered. Given the emphasis on sustainability and recurring revenue from consumables, investors should weigh the growth projections against these inherent risks. Overall, Molbio Diagnostics’ IPO could serve as a critical touchpoint for investors looking to navigate the evolving landscape of the Indian diagnostic market.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)